Literature DB >> 7645156

Urodynamic evaluation of stress incontinence.

E J McGuire1.   

Abstract

A careful history points the urodynamic examination in the right direction and enables the examiner to ask the correct questions. The individual who does the test is the only reliable interpreter of the results of that study. No urodynamic technique is as sensitive or specific as a blood glucose, or even an electrocardiogram. A history of urgency and urge incontinence suggests uninhibited contractility and is a better index of that condition than a cystometrogram. Leakage occurring shortly after a previous operative procedure for stress incontinence suggests type III stress incontinence. A past history of radiation, prior pelvic surgery, neurologic disease, herniated disc conditions, or prior chemotherapy all require a simple cystometrogram to rule out abnormal bladder compliance. Following a simple history and urodynamic evaluation, a physical examination should be performed, searching for urethra hypermobility and genital prolapse. Abdominal leak-point pressure testing is useful to assign broad categories of incontinence. Relatively high leak-point pressures with hypermobility suggest suspension operations will be effective. Low leak-point pressures with hypermobility often require a sling, and very low leak-point pressures with no hypermobility indicate a suitable candidate for a trial of injection therapy.

Entities:  

Mesh:

Year:  1995        PMID: 7645156

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  10 in total

Review 1.  Normal urodynamic parameters in women: part II--invasive urodynamics.

Authors:  Wally Mahfouz; Tala Al Afraa; Lysanne Campeau; Jacques Corcos
Journal:  Int Urogynecol J       Date:  2011-10-20       Impact factor: 2.894

2.  The UCLA surgical approach to sphincteric incontinence in women.

Authors:  E S Rovner; D A Ginsberg; S Raz
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

3.  Leakpoint pressures in female stress urinary incontinence.

Authors:  J M Cummings
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1997

4.  Results 1 year after the Reemex system was applied for the treatment of stress urinary incontinence caused by intrinsic sphincter deficiency.

Authors:  F Araco; G Gravante; S Dati; V Bulzomi'; F Sesti; E Piccione
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-06

5.  TVT-O vs TVT: a randomized trial in patients with different degrees of urinary stress incontinence.

Authors:  F Araco; G Gravante; R Sorge; J Overton; D De Vita; F Sesti; E Piccione
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-01-24

6.  Incontinence: do urodynamics help surgeons know when not to operate?

Authors:  Rufus Cartwright
Journal:  Nat Rev Urol       Date:  2012-06-12       Impact factor: 14.432

Review 7.  The impact of detrusor overactivity on the management of stress urinary incontinence in women.

Authors:  H Henry Lai; Michael Simon; Timothy B Boone
Journal:  Curr Urol Rep       Date:  2006-09       Impact factor: 2.862

8.  Association Between Overactive Bladder and Polyneuropathy in Diabetic Patients.

Authors:  Nermin Tanik; Serhat Tanik; Sebahattin Albayrak; Kürsat Zengin; Levent Ertugrul Inan; Emel Kiyak Caglayan; Asuman Celikbilek; Kadir Kirboga; Mesut Gurdal
Journal:  Int Neurourol J       Date:  2016-09-23       Impact factor: 2.835

9.  Transobturator tape for female stress urinary incontinence: preoperative valsalva leak point pressure is not related to cure rate or quality of life improvement.

Authors:  Je-Guk Ryu; Seong Hyeon Yu; Se Heon Jeong; Bu Hyeon Yun; Ho Song Yu; Sun-Ouck Kim; Dongdeuk Kwon
Journal:  Korean J Urol       Date:  2014-04-10

10.  Urethral Closure Pressure at Stress: A Predictive Measure for the Diagnosis and Severity of Urinary Incontinence in Women.

Authors:  Anne-Cécile Pizzoferrato; Arnaud Fauconnier; Xavier Fritel; Georges Bader; Philippe Dompeyre
Journal:  Int Neurourol J       Date:  2017-06-21       Impact factor: 2.835

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.